Skip to content

Author

K. Zeng

We have 5 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial

Background The benefit from adjuvant chemotherapy varies among patients with postmenopausal, node-positive, hormone receptor-positive breast cancer. Genomic assays identify patients likely to benefit from chemotherapy but are expensive and tissue consuming. AI-enabled biomarkers may provide scalable alternatives. We pe...

A. Thompson, A. Meisner, K. Albain et al. · 0 citations
Open access Sep 2026

A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer

PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk in clinic...

T. Bachelot, S. Chabaud, J. Lemonnier et al. · 1 citation
#artificial intelligence Review Oct 2026

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.

Jungkyu Park, D. Biswas, J. Cappadona et al. · 0 citations
Open access Sep 2026

An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial

BACKGROUND The prescribing of adjuvant chemotherapy for patients with breast cancer must balance the survival benefit against treatment-related toxicities. TAILORx, a phase 3 randomized clinical trial, demonstrated that endocrine therapy alone was, on average, noninferior to chemoendocrine therapy for patients classifi...

Nancy Chan, Cerise Tang, D. Biswas et al. · 1 citation
#artificial intelligence Preprint Sep 2026

Causal multi-modal AI for personalized chemosensitivity prediction

The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.

D. Biswas, Jeroen Berrevoets, A. McClean et al. · 3 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.